CRISPR patents revoked following Nobel Prize winners’ withdrawal

The patents have been officially revoked following the pair's voluntary decision to withdraw them | Withdrawal follows unfavourable preliminary opinion from the EPO | Cancelled patents not expected to impact ongoing licensing agreements for CRISPR technology, says licensor.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Final call: Who are the world’s best in-house counsel?

16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

Europe

Italian medtech startup beats larger US rival in UPC dispute

15 January 2026 Case between AorticLab and Emboline has implications for UPC playbook in terms of requesting security for costs, and conditional counterclaims.

Europe

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

13 January 2026 As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.

More features

Pearce IP grows practice with senior patent hire

Sanofi suffers setback in insulin monopoly dispute

Firm adds seven-lawyer team in second major merger

Eli Lilly’s Mounjaro tops list of cyber squatter targets

The quantum advantage: IP considerations for the next generation of life sciences innovation

Fed Circ overturns PTAB decision in $83.4m DNA case

Simpson Thacher adds ‘exemplary’ litigator with emerging tech expertise

AI is transforming top 100 innovators, shows index

CRISPR patents revoked following Nobel Prize winners’ withdrawal

More on this story

Editor's picks

Editor's picks

More features